Real-World study to track Jivi's bleeding prevention in kids
NCT ID NCT07088458
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will follow 40 children aged 7 to 12 with hemophilia A who are already prescribed damoctocog alfa pegol (Jivi) to prevent bleeding. Researchers will collect data from routine care, including bleeding episodes and treatment patterns, over two years. The goal is to understand how well the drug works in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
damoctocog alfa pegol (Jivi)
What this could lead to
If successful, this study could provide real-world evidence on how well Jivi prevents bleeding episodes in children, helping doctors tailor treatment.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection. It does not test a new drug or compare treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••